These results show that the testosterone tetrad plays an important role in the tumor growth, disease progression, and therapy response of highly metastatic PCa cells in vivo, and indicate, at least in part, that the pharmacological targeting of SHBG or SRD5A1 synergistically enhance the therapeutic effect of conventional anticancer therapy, in vivo. This evidence concerns the gene SRD5A1 and posterior cortical atrophy.